![Thermo Fisher Scientific Announces FDA Approval of Oncomine Dx Target Test as the First NGS-Based Companion Diagnostic to Aid in Therapy Selection for Patients with RET Mutations/Fusions in Thyroid Cancers | Business Thermo Fisher Scientific Announces FDA Approval of Oncomine Dx Target Test as the First NGS-Based Companion Diagnostic to Aid in Therapy Selection for Patients with RET Mutations/Fusions in Thyroid Cancers | Business](https://mms.businesswire.com/media/20220927005298/en/1387941/23/Thermo_Fisher_Scientific.jpg)
Thermo Fisher Scientific Announces FDA Approval of Oncomine Dx Target Test as the First NGS-Based Companion Diagnostic to Aid in Therapy Selection for Patients with RET Mutations/Fusions in Thyroid Cancers | Business
![Thermo Fisher Acquires Point-of-Care Molecular Diagnostics Provider Mesa Biotech - Industry News - mobile.Labmedica.com Thermo Fisher Acquires Point-of-Care Molecular Diagnostics Provider Mesa Biotech - Industry News - mobile.Labmedica.com](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2021-01-20/SDD-2439C.jpg)
Thermo Fisher Acquires Point-of-Care Molecular Diagnostics Provider Mesa Biotech - Industry News - mobile.Labmedica.com
![Thermo Fisher Scientific Collaborates with Artificial To Accelerate COVID-19 Diagnostics | Technology Networks Thermo Fisher Scientific Collaborates with Artificial To Accelerate COVID-19 Diagnostics | Technology Networks](https://assets.technologynetworks.com/production/dynamic/images/content/347016/thermo-fisher-scientific-collaborates-with-artificial-to-accelerate-covid-19-diagnostics-347016-960x540.jpg?cb=11165273)
Thermo Fisher Scientific Collaborates with Artificial To Accelerate COVID-19 Diagnostics | Technology Networks
![Thermo Fisher bets big on blood cancer, immune diagnostics with $2.6B Binding Site buyout - MedCity News Thermo Fisher bets big on blood cancer, immune diagnostics with $2.6B Binding Site buyout - MedCity News](https://medcitynews.com/uploads/2022/10/GettyImages-97206143-600x400.jpg)
Thermo Fisher bets big on blood cancer, immune diagnostics with $2.6B Binding Site buyout - MedCity News
![New IVD System Enables Assay Developers and Clinical Laboratories to Accelerate Molecular Diagnostics Growth New IVD System Enables Assay Developers and Clinical Laboratories to Accelerate Molecular Diagnostics Growth](https://mma.prnewswire.com/media/1682264/Thermo_Fisher_Scientific___QuantStudio_7_Pro_Dx_Real_Time_PCR_System.jpg?w=200)
New IVD System Enables Assay Developers and Clinical Laboratories to Accelerate Molecular Diagnostics Growth
![Thermo Fisher Scientific partners with AstraZeneca to develop solid tissue and blood-based companion diagnostic test for Tagrisso – PharmaLive Thermo Fisher Scientific partners with AstraZeneca to develop solid tissue and blood-based companion diagnostic test for Tagrisso – PharmaLive](https://www.pharmalive.com/wp-content/uploads/2023/01/ThermoFisher-AstraZeneca-475x400.jpg)
Thermo Fisher Scientific partners with AstraZeneca to develop solid tissue and blood-based companion diagnostic test for Tagrisso – PharmaLive
![Thermo Fisher Scientific announces collaboration with Ortho Clinical Diagnostics – The Journal of Healthcare Contracting Thermo Fisher Scientific announces collaboration with Ortho Clinical Diagnostics – The Journal of Healthcare Contracting](https://www.jhconline.com/wp-content/uploads/Thermo-Fisher-Sci-sign-WEB.jpg)